Page last updated: 2024-10-25

ciglitazone and Dermatitis, Atopic

ciglitazone has been researched along with Dermatitis, Atopic in 2 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Dermatitis, Atopic: A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rühl, R1
Dahten, A2
Schweigert, FJ1
Herz, U1
Worm, M2
Koch, C1
Ernst, D1
Schnöller, C1
Hartmann, S1

Other Studies

2 other studies available for ciglitazone and Dermatitis, Atopic

ArticleYear
Inhibition of IgE-production by peroxisome proliferator-activated receptor ligands.
    The Journal of investigative dermatology, 2003, Volume: 121, Issue:4

    Topics: Animals; CD40 Antigens; Cells, Cultured; Dermatitis, Atopic; Female; Humans; Hypoglycemic Agents; Im

2003
Systemic PPARgamma ligation inhibits allergic immune response in the skin.
    The Journal of investigative dermatology, 2008, Volume: 128, Issue:9

    Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dermatitis, Atopic; Disease Models,

2008